Business
Change to Director Shareholding
Change to Director Shareholding.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 3633A N4 Pharma PLC 28 May 2019 \n\n28 May 2019\nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\n \nChange to Director Shareholding\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has been advised that Luke Cairns, a non-executive director of the Company, now holds 142,660 ordinary shares in the Company (\"Ordinary Shares\"), representing approximately 0.14 per cent. of the Company's issued share capital.\n \nThe change to Luke Cairn's shareholding is a result of a loss of 197 Ordinary Shares following the administration proceedings of Beaufort Securities Limited (\"Beaufort\"), the stockbroker where Mr Cairns formerly held his Ordinary Shares. Administrators of Beaufort were unable to fully reconcile the Ordinary Shares that were held in the Beaufort pooled broking account and have applied the shortfall in Ordinary Shares across Beaufort's clients in proportion to their entitlements to it. Mr Cairns now holds his Ordinary Shares with a different stockbroker. Mr Cairns has received compensation of £57.62 from the Financial Services Compensation Scheme for the loss of the 197 Ordinary Shares.\n \nEnquiries: \n\n\n\nN4 Pharma Plc\nNigel Theobald, CEO\n\n\n \nVia Scott PR\n \n\n\n\n\nAllenby Capital Limited\nJames Reeve/Asha Chotai\n \n\n\nTel: +44(0)203 328 5656\n\n\n\n\nScott PR\nGeorgia Smith\n \n\n\n \nTel: +44(0)1477 539 539\n \n\n\n\n \nAbout N4 Pharma\n \nN4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.\n \nN4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.\n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authori...